1st-line treatment of patients with high-grade non-Hodgkin's lymphoma: Similar effectiveness with R-CHOP-14 or R-CHOP-21 Data from the German prospective TLN Registry

被引：0
|
作者：
Knauf, W. [1 ]
Abenhardt, W. [2 ]
Mohm, J. [3 ]
Rauh, J. [4 ]
Grugel, R. [5 ]
Harde, J. [5 ]
Jaenicke, M. [5 ]
Marschner, N. [6 ]
机构：
[1] Onkol Gemeinschaftspraxis, Frankfurt, Germany
[2] Munchner Onkol Praxis Elisenhof, Munich, Germany
[3] Onkol Gemeinschaftspraxis, Dresden, Germany
[4] Fachinternist Gemeinschaftspraxis U Therapiezentr, Witten, Germany
[5] iOMEDICO, Freiburg, Germany
[6] Praxis Interdisziplinare Onkol & Hamatol, Freiburg, Germany
来源：
Oncology Research and Treatment | 2015年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V75
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [31] Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL) after dose-dense rituximab: Results of the DENSE-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    Pfreundschuh, M.
    Zeynalova, S.
    Poeschel, V.
    Haenel, M.
    Schmitz, N.
    Ho, A. D.
    Reiser, M.
    Loeffler, M.
    Schubert, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Peg-filgrastim (Peg-F) on day 4 of (R-)CHOP-14 chemotherapy compared to day 2 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of a randomized trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL)
    Hartmann, F.
    Zeynalova, S.
    Nickenig, C.
    Reiser, M.
    Lengfelder, E.
    Duerk, H.
    de Witt, M.
    Schubert, J.
    Loeffler, M.
    Pfreundschuh, M. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] CNS-disease in elderly patients treated with modern chemotherapy (CHOP-14) with or without rituximab: An analysis of CNS events in the RICOVER-60 trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    Boehme, Volknaar
    Zeynalova, Samira
    Lengfelder, Eva
    Franke, Astrid
    Reiser, Marcel
    Steinhauet, Hans
    Clemens, Michael
    Nickenig, Christine
    de Witt, Maike
    Loeffler, Markus
    Pfreundschuh, Michael
    Schmitz, Norbert
    [J]. BLOOD, 2007, 110 (11) : 159A - 160A
  • [34] CNS RECURRENCE IN AGGRESSIVE LYMPHOMA TREATED WITH MODERN CHEMOTHERAPY (CHOP-14) WITH OR WITHOUT RITUXIMAB: AN ANALYSIS OF CNS-EVENTS IN ELDERLY PATIENTS TREATED IN THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN'S LYMPHOMA STUDY GROUP (DSHNHL)
    Schmitz, N.
    Boehme, V.
    Zeynalova, S.
    Lengfelder, E.
    Reiser, M.
    Steinhauer, H.
    Clemens, M.
    Nickenig, C.
    Loeffler, M.
    Pfreundschuh, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 158 - 158
  • [35] Male Sex Is Associated with Lower Rituximab Trough Serum Levels and Evolves as a Significant Prognostic Factor in Elderly Patients with DLBCL Treated with R-CHOP: Results From 4 Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL).
    Pfreundschuh, Michael
    Murawski, Niels
    Zeynalova, Samira
    Poeschel, Viola
    Reiser, Marcel
    Ho, Anthony D.
    Nickenig, Christina
    Wessendorf, Swen
    Metzner, Bernd
    Grass, Sandra
    Schubert, Joerg
    Loeffler, Markus
    Schmitz, Norbert
    [J]. BLOOD, 2009, 114 (22) : 1431 - 1431
  • [36] R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project
    LaCasce, Ann
    Vandergrift, Jonathan L.
    Rodriguez, Maria A.
    Crosby, Allison L.
    Lepisto, Eva M.
    Czuczman, Myron S.
    Nademanee, Auayporn P.
    Blayney, Douglas W.
    Gordon, Leo I.
    Millenson, Michael
    Vanderplas, Ann
    Abel, Gregory A.
    Zelenetz, Andrew D.
    Friedberg, Jonathan W.
    [J]. BLOOD, 2009, 114 (22) : 167 - 168
  • [37] Phase II trial of R-CHOP plus maintenance rituximab for previously untreated intermediate or high grade non-Hodgkin's lymphoma (IHGNHL) with filgrastim support for older patients greater than 60 years.
    Desch, C
    Case, D
    Kalman, L
    Vongkovit, P
    Liebmann, J
    Fridman, M
    Allen, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 590S - 590S
  • [38] Six, not eight cycles of bi-weekly CHOP with rituximab (RCHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).
    Pfreundschuh, M
    Kloess, M
    Schmits, R
    Zeynalova, S
    Lengfelder, E
    Franke, A
    Steinhauer, H
    Reiser, M
    Clemens, M
    Nickenig, C
    de Wit, M
    Hoffmann, M
    Mertelsmann, R
    Metzner, B
    Ho, A
    Truemper, L
    Eimermacher, H
    Mergenthaler, H
    Liersch, R
    Duehrsen, U
    Balleisen, L
    Hartmann, F
    Poeschel, V
    Schmitz, N
    Loeffler, M
    [J]. BLOOD, 2005, 106 (11) : 9A - 9A
  • [39] Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: Results from prospective trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
    Hohloch, Karin
    Ziepert, Marita
    Truemper, Lorenz
    Buske, Christian
    Held, Gerhard
    Poeschel, Viola
    Chapuy, Bjoern
    Altmann, Bettina
    [J]. EJHAEM, 2020, 1 (01): : 181 - 187
  • [40] Dose-dense rituximab in combination with biweekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of a phase-I/II and pharmacokinetic study of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).
    Poeschel, Viola
    Nickelsen, Maike
    Hanel, Mathias
    Kremers, Stephan
    Wessendorf, Swen
    Eimermacher, Hartmut
    Peter, Norma
    Wenger, Michael
    Reiser, Marcel
    Schmitz, Norbert
    Pfreundschuh, Michael
    [J]. BLOOD, 2006, 108 (11) : 774A - 775A
12345